Well, we are a data provider. I think the relationship with PMPRB is probably a good example of where we have data. Again, all of the legal arrangements, all of the arrangements allow us to pass that data on in a very appropriate way, under appropriate conditions, to someone else to do another function in the health system. I think we would have the ability to do that. In fact, the drug database that we are currently building, that's been spoken of this morning, wouldn't be able to do everything, but, again, I think it would have some power to assist in that process.
Given how expensive it is to collect data and given it's expensive to standardize it, it does make sense to understand what exists now and how that might feed into or support post-market surveillance or any other number of health activities.